<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849484</url>
  </required_header>
  <id_info>
    <org_study_id>HIPSPA2013</org_study_id>
    <nct_id>NCT01849484</nct_id>
  </id_info>
  <brief_title>Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy</brief_title>
  <acronym>HIPPO-SPARE 01</acronym>
  <official_title>Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial examines possible enhancements in live quality and neurocognitive
      functions in patients after radiotherapy of the neurocranial area with hippocampal sparing.
      Although the hippocampus has a crucial role in regard to neurocognition and memory,
      hippocampal region has been relatively disregarded in radiotherapy of neurocranium so far.
      Brain metastases in the hippocampal region are very rare and an infiltration of the
      hippocampus by meningioma or by pituitary adenoma just occurs when volume of the tumor is
      very high. This study aims to reduce the radiation dose in the hippocampal region to improve
      the quality of live and neurocognitive functions in patients without degrading prognosis or
      increasing probability of brain metastases in hippocampal region.

      Primary endpoint of the trial is quality of live and neurocognitive functions in patients
      after radiation of neurocranial region with hippocampal sparing compared with conventional
      radiotherapy of the neurocranial region without hippocampal sparing. Secondary endpoints are
      cerebral recurrence rate in hippocampal region and overall survival. It is planned to include
      a total number of 150 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quality of live and neurocognitive functions</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cerebral recurrence rate in hippocampal region</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Radiation of Neurocranial Region</condition>
  <arm_group>
    <arm_group_label>hippocampal sparing radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation according to indication with hippocampal sparing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation according to indication without hippocampal sparing</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation according to indication with hippocampal sparing</intervention_name>
    <description>Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy</description>
    <arm_group_label>hippocampal sparing radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation according to indication without hippocampal protection</intervention_name>
    <description>Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimum age 18

          -  diseases indicating a radiotherapy of neurocranial area (histologically or
             image-guided confirmed (skull base)meningioma,pituitary adenoma,brain metastases,
             SCLC)

          -  indication for a local radiotherapy in neurocranial area or for a radiation of whole
             neurocranium

          -  Karnofsky-State ≥ 50%

          -  patient has understand content of study protocol

          -  Signed study-specific consent form prior to therapy

        Exclusion Criteria

          -  pregnant or nursing women

          -  Fertile patients who refuse effective contraception during study treatment

          -  persistent drug and/or alcohol abuse

          -  prior radiotherapy of neurocranial region

          -  patients not able or willing to behave according to study protocol

          -  in the case of malignancy: more than 3 brain metastases

          -  in the case of malignancy: brain metastases in hippocampal region or in the
             hippocampus avoidance zone

          -  GTV in hippocampal region or in the hippocampus avoidance zone

          -  patients in care

          -  patients who are not able to speak German

          -  conditions that preclude the application of MRT (e.g. magnetic implants, cardiac
             pacemaker)

          -  on-treatment participation on other trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strahlenklinik, Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainer Fietkau, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretariat@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Godehard Lahmer, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>godehard.lahmer@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Fietkau, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Godehard Lahmer, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>godehard.lahmer@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Rainer Fietkau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Godehard Lahmer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <last_update_submitted>July 29, 2016</last_update_submitted>
  <last_update_submitted_qc>July 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meningioma</keyword>
  <keyword>skull base meningioma</keyword>
  <keyword>pituitary adenoma</keyword>
  <keyword>brain metastases</keyword>
  <keyword>small cell lung carcinoma</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

